NXI Therapeutics AG
NXI Therapeutics creates tomorrow's disruptive immunotherapies that maintain immunocompetence. The company has identified 3rd generation isoform-specific BET inhibitors that provide a potent, autoimmune-selective immunomodulation. This unique profile may truly unlock the potential of epigenetic BET inhibition for the treatment of autoimmune and inflammatory diseases. The company focuses on clinical applications in T cell-mediated autoimmune skin conditions.
Date, time and room information
May 5, 14:45 - 15:00, room Singapore
Category
Emerging biotech company
Title of the presentation
Leveraging a targeted epigenetic approach to treat autoimmunity.
Speaker information
| Name | Position | Institution |
|---|---|---|
| Ruben Herrendorff | CEO | NXI Therapeutics AG |
